Transcenta Holding Limited · HKEX:6628
Transcenta — H1 2025 Earnings Presentation
33 slides from Transcenta's earnings presentation, Aug 28, 2025
Slide 1: 2025 Interim Results Update
Transcenta Holding Limited 2025 Interim Results Update August 28, 2025
Slide 2: Forward-looking Statement of Transcenta Holding Limited
Forward-looking Statement of Transcenta Holding Limited • The information and opinions contained in this presentation are provided as of the date of this presentation, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after
Slide 3: Agenda
Key Highlights| Dr. Xueming Qian Business Update| Dr. Xueming Qian & Dr. Charlie Qi & Mr. Weiwei Liang Agenda Financial Update | Mr. Weiwei Liang Outlook | Dr. Xueming Qian Q&A | All 3
Slide 4: Key Highlights
Key Highlights Dr. Xueming Qian Chairman and CEO 4
Slide 5: Transcenta Global Strategy and Integrated Capabilities
Transcenta Global Strategy and Integrated Capabilities Industry Leading Antibody Generation and Bio-process Platforms Amsterdam Beijing Clinical / Regulatory Clinical / Regulatory Shanghai Clinical/ Business Development New Jersey Clinical / Regulatory Top-notch Discovery & Translational Los Angeles
Slide 6: Diversified and Differentiated Pipeline
Diversified and Differentiated Pipeline Drug Pivotal Target Modality indications Preclinical IND Phase 1 Phase 2 Rights Partner candidate Phase 3 G/GEJC 1L Combo with PD1/Chemo Osemitamab Claudin18.2 mAb G/GEJC 1L Combo with Chemo Global In-house (TST001) PDAC 1L Combo with Chemo TST003 GREMLIN-1 (F
Slide 7: Key Pipeline Progress and Data Presentations
Key Pipeline Progress and Data Presentations Oncology Osemitamab (TST001) (CLDN18.2) • The Hong Kong patents were granted to us • Presented OS data for 1L combo with PD1 inhibitor and chemo at ASCO 2025 TST003 (GREMLIN-1) • Currently being tested in a multi-centered global FIH trial in the U.S. and
Slide 8: Business Update
Business Update Dr. Xueming Qian Chairman and CEO & Dr. Charlie Qi EVP, Global Clinical Development & Mr. Weiwei Liang Acting CFO, SVP, Business Development Transaction & Corporate Strategy 8
Slide 9: Oncology - Osemitamab (TST001)
Oncology - Osemitamab (TST001) A Best-in-Class Anti-CLDN18.2 Antibody Target Sales: USD $1B Sales in First-line G/GEJC Alone Multi-billion USD Potential in G/GEJC PDAC and NSCLC Global Phase 3 Ready Asset Robust CMC BIC Profile • Extensive China and • Industry leading US clinical datasets continuous
Slide 10: Osemitamab Phase 1/2 Trial Overview
Oncology - Osemitamab (TST001) Phase 1/2 Trial Overview - Study Design: Key G/GEJC Cohorts for First-line G/GEJC TranStar102 (China) TranStar101 (U.S.) • Cohort C: Osemitamab + CAPOX • Cohort G: Osemitamab • Cohort A: Osemitamab + FOLFOX + Study • CLDN18.2 ≥10% ≥1+ CAPOX + Nivolumab Nivolumab Design
Slide 11: Encouraging Efficacy for Combo with PD1 and Chemo in 1L G/GEJC
Oncology - Osemitamab (TST001) Encouraging Efficacy for Combo with PD1 and Chemo in CLDN18.2+ 1L G/GEJC Progression-Free Survival [1] Overall Survival [1] ASCO 2025, PFS for Patients with PDL1 CPS & CLDN18.2 Known ASCO 2025, OS for Patients with PDL1 CPS & CLDN18.2 Known Overall (N=66) PFS Median PF
Slide 12: Superior Efficacy than Historical Benchmark – Cross Study Comparison
Oncology - Osemitamab (TST001) Superior Efficacy than Historical Benchmark – Cross Study Comparison Osemitamab+PD1+Chemo in CLDN18.2+ (≥40%, ≥2+) 1L G/GEJC [1] Has Better Efficacy than Nivolumab+Chemo Data in Checkmate 649* and Zolbetuximab+Chemo Data in GLOW** OS mPFS 21.7 16.6 14.4 13.8 8.2 7.7 Z
Slide 13: Substantial Commercial Opportunities in the Front-line G/GEJC and Beyond
Oncology - Osemitamab (TST001) Substantial Commercial Opportunities in the Front-line G/GEJC and Beyond First-line G/GEJC Peri-Operative GC Combo with SOC Potentially First Mover (Checkpoint Inhibitor / Anti-CLDN18.2 mAb Chemotherapy) >100K addressable patients globally * [1] ~70K addressable patien
Slide 14: Build Leadership in the Treatment of CLDN18.2 Positive Tumors
Oncology - Osemitamab (TST001) Build Leadership in the Treatment of CLDN18.2 Positive Tumors with Osemitamab and Follow-on Agents Advancing Toward Our Vision Osemitamab as the cornerstone of the treatment for CLDN18.2 positive tumors Solidify leadership by developing the next generation anti-CLDN18.
Slide 15: Portfolio of CLDN18.2 Targeted Therapies
Oncology - Portfolio of CLDN18.2 Targeted Therapies Benefiting Boarder Patient Population with Differentiated Assets Osemitamab TST106 18B10 based RDC Targeted Radiopharmaceutical Modality Monoclonal antibody Bispecific ADC Therapy Tumor cell killing Enhanced immune-cell mediated Direct tumor cell k
Slide 16: Oncology - TST003
Oncology - TST003 A Novel Target with Potential for Multiple Solid Tumor Indications CRC $37B[1] CRPC $12B[1] NSCLC $64B[1] GC $12B[1] Grem1 is negatively correlated with outcome in GC MSS CRC mCRPC TST003+/-VEGFRi 1400 with hPBMCs TST003+/-VEGFRi 1400 1200 with hPBMCs Tumor Volume (mm3) 1200 1000 T
Slide 17: Oncology - TST786
Oncology - TST786 A Next Generation Trispecific Antibody Candidate Targeting PD1-VEGF and GREMLIN-1 Milestone Lead molecule has been obtained and preclinical testing is ongoing • VEGF and PD1 combination is clinical validated combination for enhancing immunotherapy efficacy • Existing PD1-VEGF bispe
Slide 18: Oncology - TST013
Oncology - TST013 An Improved LIV-1-targeting ADC for Breast Cancer and other Solid Tumors Breast $44B[1] NSCLC $64B[1] Cancer A Clinically Validated Target in Breast Cancer with Significant Potential in Other Solid Tumors LIV-1 has high prevalence across multiple solid tumors • breast cancer, lung
Slide 19: TST013 Best-in-class LIV-1 ADC
Oncology - TST013 TST013 is a Best-in-class LIV-1 ADC Designed to Circumvent Issues Encountered with the First-generation ADC TST013 Induces Strong Bystander Effect, Durable Tumor Regression & More Potent Anti-Tumor Activity Than LV at Low Dose Potent tumor inhibition in LIV-1 expressing cell line M
Slide 20: Future Oncology Strategy
Future Oncology Strategy Immunotherapy TST786 PD1/VEGF/GREM1 Trispecific + CLDN18.2 – FGFR2b – LIV1 ADC Osemitamab bispecific ADC bispecific ADC Targeted Therapy
Slide 21: Non-oncology – Blosozumab (TST002)
Non-oncology – Blosozumab (TST002) Anti-sclerostin mAbs are Poised to Address the Huge Unmet Needs of Osteoporosis in China High Unmet Medical Needs with Large Market Potential Aging population in China Rising incidence of OP fractures Rising market size of anti- Target Sales: in China sclerostin d
Slide 22: Potential Better Efficacy of Blosozumab than Romosozumab & Denosumab
Non-oncology – Blosozumab (TST002) Potential Better Efficacy of Blosozumab (TST002) than Romosozumab & Denosumab % change from baseline of BMD at lumbar Dual Mechanisms spine after 1 year therapy More potent than all currently available anti-OP medicines that address only one aspect of bone mass los
Slide 23: Encouraging Efficacy Data Justifying Further Clinical Development
Non-oncology - Blosozumab (TST002) Encouraging Efficacy Data Justifying Further Clinical Development, with the potential for Q2M or Q3M dosing Study population: SAD Study Design • Subjects with reduced BMD(-3.5≤ T value<-1.0) 1200mg，n=6+2 • Age 45-70yrs • Postmenopausal women or older men 800mg，n=6+
Slide 24: Non-oncology - TST801
Non-oncology - TST801 A FIC Bifunctional Fusion Protein Targeting Two Validated B-cell Targets in Autoimmune Diseases with Multi-billion-dollar Potentials $13B[1] $22B[2] $9B[2] $5B[1] $10B[2] $6B[2] SLE gMG[1] IgAN [1] LN pSS [1] ITP [1] A First-in-class Bifunctional Fusion Protein of an Anti-BAFF
Slide 25: Non-oncology - TST801
Non-oncology - TST801 A FIC Bifunctional Fusion Protein Targeting Two Validated B-cell Targets in Autoimmune Diseases with Multi-billion-dollar Potentials TST801 is more potent in BAFF dependent Cell-based signaling pathway blocking assay than Telitacicept and ALPN303, at higher BAFF concentration a
Slide 26: Non-oncology - TST808
Non-oncology - TST808 A Best-In-Class Humanized Antibody against a Validated Target in IgAN IgAN Market • IgAN is a rare autoimmune kidney disease with high unmet medical needs. Estimated Market Size by 2032 • It is one of the leading causes of renal failure. Up to 40% of patients $9B in major marke
Slide 27: Upcoming Milestones
Upcoming Milestones Osemitamab Blosozumab TST003 TST013 TST801 TST808 (TST001) (TST002) • Advance global • Start the • Continue • Continue • Continue • Continue pivotal trial for First- multiple Phase 1 trial IND- IND- IND- line G/GEJ cancer ascending dose to obtain enabling enabling enabling • Pres
Slide 28: Process Development & Manufacturing
Process Development & Manufacturing World Class CMC Team, Bioprocessing Platform and Infrastructure Our Strengths Advanced Perfusion Technology Faster Quality Significant Cost Saving We have Preparation for launch Advanced Technology and Platform High Quality Output • Osemitamab Phase 3 clinical • I
Slide 29: Business Development
Business Development Multinational Partners to Maximize Value Current Priorities Asset Out-License/NewCo Technology Out-license/ Co- dev In-License/Co-dev Osemitamab TST003 TST013 • Perfusion Bioprocessing Novel programs and technologies Platform that enhance our portfolio and Blosozumab TST801 TST8
Slide 30: Financial & Outlook
Financial & Outlook Mr. Weiwei Liang Acting CFO, SVP, Business Development Transaction & Corporate Strategy 30
Slide 31: 2025 1H Financial Results (Non-IFRS)
20251H Financial Results (Non-IFRS) Revenue RMB 2.7 million Other Income RMB 11.4 million 11.4 4.6 9.6 2.7 2024 1H 2025 1H 2024 1H 2025 1H R&D Expenses RMB 70.8 million SG&A Expenses RMB 24.9 million 95.5 70.8 26.1 24.9 2024 1H 2025 1H 2024 1H 2025 1H Bank deposits and cash as of Jun 30, 2025 is app
Slide 32: Outlook
Outlook Integrated Platform, Cutting-edge Technology, Differentiated and Competitive Biologics Business Clinical Development Research CMC & CDMO Development & Finance • Advance global Phase 3 • Continue product and • Expand pipeline • Enhance platform trial for osemitamab technology partnership with
Slide 33: Thank You
ee Ge TRANSCENTA INNOVATE TO EXCEL THANK YOU!